Skip to main content
  1. Home

Submission Tool and Repository Measure Database

As the Centers for Medicare & Medicaid Services (CMS) consensus-based entity (CBE), Battelle Memorial Institute (Battelle) discloses complete information (e.g., full measure specifications, coding logic, algorithms) regarding each measure to the public for the purpose of evaluating, analyzing, or displaying of each measure for endorsement consideration. If an interested party wishes to attain complete measure information for the use and/or implementation of a measure, the interested party should contact the measure steward. Contact information for the measure steward can be found under the “Point of Contact” section of the respective measure page within the Submission Tool and Repository (STAR). Battelle is not responsible for, nor is privy to the measure use agreements that may be established between a measure steward and an interested party.

To obtain a copy of the full measure submission forms for measures endorsed prior to Fall 2022 cycle, please contact [email protected].

No Filters Selected
          CBE ID Title Steward Endorsement Cycle Status Date of Last Endorsement Decision
          1855 Quantitative HER2 evaluation by IHC uses the system recommended by the ASCO/CAP guidelines College of American Pathologists Endorsement Removed
          1857 HER2 negative or undocumented breast cancer patients spared treatment with HER2-targeted therapies American Society of Clinical Oncology Endorsement Removed
          1858 Trastuzumab administered to patients with AJCC stage I (T1c) – III human epidermal growth factor receptor 2 (HER2) positive breast cancer who receive adjuvant chemotherapy American Society of Clinical Oncology Endorsed
          1859 RAS gene mutation testing performed for patients with metastatic colorectal cancer who receive anti-epidermal growth factor receptor monoclonal antibody therapy American Society of Clinical Oncology Endorsed
          1860 Patients with metastatic colorectal cancer and RAS gene mutation spared treatment with anti-epidermal growth factor receptor monoclonal antibodies American Society of Clinical Oncology Endorsed
          1878 HER2 testing for overexpression or gene amplification in patients with breast cancer American Society of Clinical Oncology Endorsement Removed
          1879 Adherence to Antipsychotic Medications for Individuals with Schizophrenia Centers for Medicare & Medicaid Services Endorsed
          1880 Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder Centers for Medicare & Medicaid Services Endorsement Removed
          1884 Depression Response at Six Months- Progress Towards Remission MN Community Measurement Endorsed
          1885 Depression Response at Twelve Months- Progress Towards Remission MN Community Measurement Endorsement Removed
          Displaying 861 - 870 of 1219

          The Submission Tool and Repository (STAR) is a measure database of quality performance measures that have been submitted to the previous consensus-based entity for endorsement review. The STAR database will be updated regularly as new and maintenance measures are submitted to the Partnership for Quality Measurement for endorsement review. Battelle will be providing additional enhancements to the STAR database as measure information is submitted in order to better support the accessibility of timely and accurate measure information for all interested parties.